Under the transaction, Boston Scientific will acquire the remaining 65 percent stake in Cryterion that it didn’t already own.
The deal will give Boston Scientific access to both cryothermal and radiofrequency single-shot balloon-based ablation therapies.
Although Cryterion’s technology hasn’t been approved for use in any country, initial clinical trials have shown promise, according to Keegan Harper, president and CEO of Cryterion Medical.
More articles on supply chain:
3 latest FDA approvals
Mercy shares EHR data with J&J to evaluate medical device safety
Influx of medical waste washes up on Florida beach
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.